Pharmacotherapy and growth factors in the treatment of short bowel syndrome

Seminars in Pediatric Surgery

Volumn 10, Issue 2, 2001, Pages 81-90

  Schwartz, Marshall Z ^a,b,c   Kuenzler, Keith A ^a,b,c  

^a AI DuPont Hospital for Children ^*

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIDIARRHEAL AGENT; ATROPINE PLUS DIPHENOXYLATE; CIMETIDINE; CODEINE; COLESTYRAMINE; GLUCAGON LIKE PEPTIDE 2; GLUTAMINE; GROWTH FACTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; HUMAN GROWTH HORMONE; LOPERAMIDE; OCTREOTIDE; OMEPRAZOLE; OPIATE; OPIATE AGONIST; PAREGORIC; PROTON PUMP INHIBITOR; SCATTER FACTOR; SOMATOMEDIN C; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SUCRALFATE; TEDUGLUTIDE; UNCLASSIFIED DRUG;

CHILD; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ELECTROLYTE BALANCE; FLUID BALANCE; GASTROINTESTINAL SYMPTOM; GENE THERAPY; HUMAN; INTESTINE ABSORPTION; INTESTINE FUNCTION; INTESTINE TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SHORT BOWEL SYNDROME; TOTAL PARENTERAL NUTRITION;

EID: 0035011552     PISSN: 10558586     EISSN: None     Source Type: Journal    
DOI: 10.1053/spsu.2001.22385     Document Type: Article

References (113)

1. Hypersecretion of gastrin associated with the short bowel syndrome
2. Small bowel resection and gastric acid hypersecretion
3. Improved nutrient absorption after cimetidine in short-bowel syndrome with gastric hypersecretion
4. Effect of ranitidine on gastric acid hypersecretion in an infant with short bowel syndrome
5. Effects of cimetidine on jejunostomy effluents in patients with severe short-bowel syndrome
6. Effect of omeprazole on intestinal output on the short bowel syndrome
7. Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection
8. Loperamide: A review of its pharmacological properties and therapeutic efficacy in diarrhoea
9. Mechanisms of action of loperamide
10. Loperamide: A new antidiarrheal agent in the treatment of chronic diarrhea
11. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea
12. A double-blind crossover comparison of loperamide with diphenoxylate in the symptomatic treatment of chronic diarrhea
13. Inhibition of post-prandial pancreatic and biliary secretion by loperamide in patients with short bowel syndrome
14. Inhibition of pancreaticobiliary secretion by loperamide in humans
15. Review article: Anti-diarrhoeal pharmacology and therapeutics
16. Diphenoxylate-atropine (Lomotil) overdose in children: An update
17. Success with intestinal failure: From adaptation to transplantation
18. Conjugated bile acid replacement therapy for short-bowel syndrome
19. Bile acid replacement therapy with cholylsarcosine for short-bowel syndrome
20. Somatostatin and somatostatin analogues: Pharmacokinetics and pharmacodynamic effects
21. Somatostatin decreases diarrhea in patients with short bowel syndrome
22. Octreotide as an adjunct to home parenteral nutrition in the management of permanent end-jejunostomy syndrome
23. Potential indications for octreotide in gastroenterology: Summary of workshop
24. Short bowel syndrome
25. Use of a long acting somatostatin analogue (SMS 201-995) in controlling a significant ileal output in a five year old child
26. Long-acting somatostatin analogue therapy and protein metabolism in patients with jejunostomies
27. Octreotide diminishes luminal nutrient transport activity, which is reversed by epidermal growth factor
28. Lack of inhibitory effect of octreotide on intestinal adaptation in short bowel syndrome in the rat
29. Somatostatin and its analogs in the short bowel syndrome
30. Effect of a long acting somatostatin analogue SMS 201-995 on jejunostomy effluents in patients with severe short bowel syndrome
31. Octreotide in dumping and short bowel syndromes
32. Glutamine metabolism by the intestinal tract
33. L-glutamine stimulates intestinal cell proliferation and activates mitogen-activated protein kinases
34. Effect of free glutamine and alanyl-glutamine dipeptide on mucosal proliferation of the human ileum and colon
35. Maintenance of small bowel mucosa with glutamine-enriched parenteral nutrition
36. The dipeptide alanylglutamine prevents intestinal mucosal atrophy in parenterally fed rats
37. Alanyl glutamine-enriched total parenteral nutrition restores intestinal adaptation after either proximal or distal massive resection in rats
38. Pathologic features of glutaminase toxicity
39. Increase in intestinal glucose absorption and hepatic glucose uptake elicited by luminal but not vascular glutamine in the jointly perfused small intestine and liver in the rat
40. L-glutamine and L-asparagine stimulate ODC activity and proliferation in a porcine jejunal enterocyte line
41. Metabolic support of the gastrointestinal tract
42. Enhanced growth of small bowel in transgenic mice overexpressing bovine growth hormone
43. In vivo and in vitro effects of human growth hormone on rat intestine ion transport
44. Human recombinant growth hormone increases small bowel lengthening after massive small bowel resection in piglets
45. Growth hormone enhances amino acid uptake by the human small intestine
46. Epidermal growth factor and human growth hormone accelerate adaptation after massive enterectomy in an additive, nutrient-dependent, and site-specific fashion
47. Gut adaptation and the insulin-like growth factor system: Regulation by glutamine and IGF-1 administration
48. Increased plasma bicarbonate and growth hormone after an oral glutamine load
49. A new treatment for patients with short-bowel syndrome
50. Growth factors and nutrients in the short bowel syndrome
51. Factors predicting a successful outcome after pharmacologic bowel compensation
52. Short-bowel syndrome-surgical treatment with long-term benefit?
53. The short-bowel syndrome: New vistas
54. Effect of growth hormone, glutamine and diet on adaptation in the short bowel syndrome: A randomized controlled study
55. Short-bowel syndrome
56. Colon as a digestive organ in patients with short bowel
57. Effect of growth hormone and glutamine on the short bowel: Five years later
58. Effect of high-dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: A randomized, double blind, cross-over, placebo controlled study
59. Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome
60. Effect of growth hormone, glutamine, and diet on body composition in short bowel syndrome: A randomized, controlled study
61. Effect humoral de la resection intestinal chez des pores en circulation sanguine croisee chronique
62. Small intestine mass of the rat is partially determined by indirect effects of luminal nutrition
63. The effect of pentagastrin on adult rat duodenal cells in culture
64. Effect of pentagastrin on gastric mucosal cells grown in tissue culture
65. Luminal gastrin stimulates growth of distal rat intestine
66. Enhancement of small intestine function by gastrin
67. Enhancement of small intestine absorption by gastrin
68. The influence of gastrin on gastrointestinal function
69. Persistent upregulation in intestinal function beyond intestinal adaptation following luminal growth factor perfusion
70. Epidermal growth factor enhances intestinal adaptation after massive small bowel resection
71. Proliferative effects of urogastrone-EGF on the intestinal epithelium
72. Intestinal overexpression of EGF in transgenic mice enhances adaptation after small bowel resection
73. Epidermal growth factor upregulates the expression of its own intestinal receptor after small bowel resection
74. Epidermal growth factor and the short bowel syndrome
75. Prolonged administration of IGF peptides enhances growth of gastrointestinal tissues in normal rats
76. Insulin like growth factor-1 prevents gut atrophy and maintains intestinal integrity in septic rats
77. Treatment with IGF-1 peptides improves function of the remaining gut following small bowel resection in rats
78. Trophic effects if interleukin-11 in rats with experimental short bowel syndrome
79. Interleukin-11 enhances small intestinal absorptive function and mucosal mass after intestinal adaptation
80. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function
81. Glucagonoma syndrome demonstrating giant duodenal villi
82. Induction of intestinal epithelial proliferation by glucagon-like peptide-2
83. Intestinal function in mice with small bowel growth induced by glucagon-like peptide 2
84. Intestinal growth-promoting properties of glucagon-like peptide 2 in mice
85. Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats
86. 2]glucagon-like peptide 2
87. Glucagon-like peptide-2 enhances intestinal function following massive small bowel resection
88. Glucagon-like pepfide-2 enhances small intestinal absorptive function and mucosal mass in vivo
89. Glucagon-like peptide-2 analogue enhances intestinal mucosal mass and absorptive function after ischemia-reperfusion injury
90. Glucagon-like peptide-2 is a potent growth factor for small intestine and colon
91. Enterotrophic effects of glucagon-like peptide-2 are enhanced by neurotensin
92. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagonlike peptide-2
93. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo
94. Basolateral D-glucose transport activity along the crypt-villus axis in rat jejunum and upregulation induced by gastric inhibitory peptide and glucagon-like peptide-2
95. Signaling mechanisms of glucagon-like peptide-2-induced intestinal epithelial cell proliferation
96. Impaired meal stimulated glucagon-like peptide-2 response in ileal resected short bowel patients with intestinal failure
97. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon
98. Biologic properties and therapeutic potential of glucagon-like peptide-2
99. Short bowel, short answer?
100. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats
101. Localization of hepatocyte growth factor in human and rat tissues: An immunohistochemical study
102. Identification of the hepatocyte growth factor receptor as the c-Met proto-oncogene product
103. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-met
104. Expression of the Met/HGF receptor in normal and neoplastic human tissues
105. Hepatocyte growth factor region specifically stimulates gastro-intestinal epithelial growth in primary culture
106. Hepatocyte growth factor accelerates restitution of intestinal epithelial cells
107. Hepatocyte growth factor in human amniotic fluid promotes the migration of fetal small intestinal epithelial cells
108. Hepatocyte growth factor enhances intestinal mucosal cell function and mass in vivo
109. Influence of hepatocyte growth factor on small intestine mucosa in vivo
110. Enhancement of intestinal adaptation by hepatocyte growth factor
111. A src-related kinase in the brush border membranes of gastrointesinal cells in regulated by c-met
112. Hepatocyte growth factor upregulates SGLT1 and GLUT5 gene expression after massive small bowel resection